Page last updated: 2024-12-04
chlamydocin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
chlamydocin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 2706 |
MeSH ID | M0049826 |
Synonyms (3)
Synonym |
---|
chlamydocin |
(3s,9s,12r)-3-benzyl-6,6-dimethyl-9-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone |
BS-1305 |
Research Excerpts
Overview
Chlamydocin is a cyclic tetrapeptide containing an epoxyketone moiety in the side chain. This makes it an irreversible inhibitor of HDACs.
Excerpt | Reference | Relevance |
---|---|---|
"Chlamydocin is a cyclic tetrapeptide containing an epoxyketone moiety in the side chain that makes it an irreversible inhibitor of HDAC." | ( Chlamydocin-hydroxamic acid analogues as histone deacetylase inhibitors. Jose, B; Kato, T; Komatsu, Y; Nishino, N; Shinta, R; Yoshida, M, 2004) | 2.49 |
"Chlamydocin is a cyclic tetrapeptide containing an epoxyketone surrogate in the side chain which makes it irreversible inhibitor of HDACs, whereas apicidins are a class of cyclic tetrapeptides that contain an ethylketone moiety as zinc ligand." | ( Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. Bhuiyan, MP; Kato, T; Maeda, S; Nishino, N; Nishino, TG; Okauchi, T; Yoshida, M, 2006) | 2.5 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (18)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (27.78) | 18.7374 |
1990's | 2 (11.11) | 18.2507 |
2000's | 7 (38.89) | 29.6817 |
2010's | 3 (16.67) | 24.3611 |
2020's | 1 (5.56) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 31.44
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.44) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 19 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |